Wells Fargo Maintains Masimo(MASI.US) With Buy Rating, Maintains Target Price $160
Buy Rating Affirmed: Masimo's Legal Stability and Growth Prospects Fuel Optimism
Masimo Analyst Ratings
Masimo (MASI) Receives a Hold From Needham
Masimo's Strategic Divestiture and Joint Venture Prospects Bolster Buy Rating
Masimo Analyst Ratings
Piper Sandler Upgrades Masimo to Overweight, Price Target at $160
Piper Sandler Maintains Neutral on Masimo, Raises Price Target to $126
Piper Sandler Keeps Their Hold Rating on Masimo (MASI)
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Masimo (MASI)
Masimo Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Masimo (MASI), Halozyme (HALO) and McKesson (MCK)
Buy Rating Affirmed for Masimo Amidst Stable Financials and Strategic Business Optimism
Stifel Upgrades Masimo to Buy, Sees Room for Share Price Appreciation
Masimo Analyst Ratings
Buy Rating Affirmed for Masimo: Strategic Developments and Positive Outlook Signal Growth
Buy Rating Affirmed for Masimo Amid Strategic Split and Enhanced Profitability Outlook
Wells Fargo Upgrades Masimo to Overweight, Cites Spinoff Plan
Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Masimo (MASI)